Reltecimod
Based on 1 Customer Validation
Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.61%
- CAS No.: 1447799-33-8
- Formule: C46H72N10O15S
- Masse moléculaire:1037.19
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pathogen-free, female BALB/c mice (Acute bacterial peritonitis was induced by i.p. administration with E. coli 018:K1)[2]
-
Dosage:1.25 or 5 mg/kg
-
Administration:i.v.; single dosage; at 4 h post infection
-
Result:Resulted in 100% survival at single dosage of 5 mg/kg, at day 6.
Resulted in 70% survival at 4 dosage (at 1, 12, 24 and 36 h post infection) of 1.25 mg/kg, at day 6.
-
Animal Model:Pathogen-free, female BALB/c mice (NSTI induced by thigh i.m. administration with Streptococcus pyogenes)[2]
-
Dosage:2.5 or 5 mg/kg
-
Administration:i.v.; single dosage; at 1 h, or at 1 h and 12 or 72 h post infection
-
Result:Resulted in 65% survival at single dosage of 2.5 mg/kg, at day 8.
Resulted in 30% survival at two dosage (1 and 12 h post infection) of 2.5 mg/kg, at day 8.
Resulted in 90% survival at single dosage (1 h post infection) of 5 mg/kg, at day 6.
-
Animal Model:Pathogen-free, female BALB/c mice [Cecal ligation and puncture (CLP) model][2]
-
Dosage:1.25, 2.5, or 5 mg/kg
-
Administration:i.v.; single dosage
-
Result:Increased day 7 survival by up to 100%.
Chemical Information
-
CAS No. 1447799-33-8
-
Appearance Solid
-
Masse moléculaire 1037.19
-
Formule C46H72N10O15S
-
Color White to off-white
-
Synonyms
AB-103
-
Sequence
{d-Ala}-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-{d-Ala}
-
Sequence Shortening
{d-Ala}-SPMLVAYD-{d-Ala}
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (96.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocole
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9641 mL | 4.8207 mL | 9.6414 mL | 24.1036 mL |
| 5 mM | 0.1928 mL | 0.9641 mL | 1.9283 mL | 4.8207 mL | |
| 10 mM | 0.0964 mL | 0.4821 mL | 0.9641 mL | 2.4104 mL | |
| 15 mM | 0.0643 mL | 0.3214 mL | 0.6428 mL | 1.6069 mL | |
| 20 mM | 0.0482 mL | 0.2410 mL | 0.4821 mL | 1.2052 mL | |
| 25 mM | 0.0386 mL | 0.1928 mL | 0.3857 mL | 0.9641 mL | |
| 30 mM | 0.0321 mL | 0.1607 mL | 0.3214 mL | 0.8035 mL | |
| 40 mM | 0.0241 mL | 0.1205 mL | 0.2410 mL | 0.6026 mL | |
| 50 mM | 0.0193 mL | 0.0964 mL | 0.1928 mL | 0.4821 mL | |
| 60 mM | 0.0161 mL | 0.0803 mL | 0.1607 mL | 0.4017 mL | |
| 80 mM | 0.0121 mL | 0.0603 mL | 0.1205 mL | 0.3013 mL |
Reltecimod Related Classifications
HY-P1698 Related Classifications
Powered by Bioz